Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 10/24/17 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
2 | |
| 10/24/17 | S-3/A | Registration statement for specified transactions by certain issuers |
|
25 | |
| 10/13/17 | 8-K | Current report filing |
|
68 | |
| 10/13/17 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
30 | |
| 09/27/17 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 09/13/17 | UPLOAD | SEC-generated letter |
|
1 | |
| 09/07/17 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 09/05/17 | S-3 | Registration statement for specified transactions by certain issuers |
|
25 | |
| 09/05/17 | 3 | Initial statement of beneficial ownership of securities |
|
2 | |
| 09/05/17 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
6 |
